Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux

NCT ID: NCT02211898

Last Updated: 2014-08-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-07-31

Brief Summary

To investigate the efficacy and safety of BNS003 on subjective symptoms such as sensation of heaviness/tiredness(dullness), tension, tingling, pain, fever or itching associated with swelling of calf and ankle due to disorder of leg venous reflux.

Conditions

Venous Insufficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BNS003

Group Type: EXPERIMENTAL

BNS003

Intervention Type: DRUG

Interventions

BNS003

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Manifestation of swelling falling into Class 1 according to Porter's classification
• With more than 2 symptoms of "sensation of heaviness/tiredness (dullness)," "tension," "tingling," "pain," "fever" or "itching" and a total score of >=3 for severity by symptoms
• Persons aged 20 years or older at the time of obtaining their informed consent and available for hospital visits. Both genders are acceptable
• Persons who have consented to participating in the study in written form with good understanding of the objective of the study, the methods, and notices for the study period

Exclusion Criteria

• Persons with edema not due to venous diseases of the legs (e.g., lymphedema, latent cardiac or renal insufficiency, etc.)
• Persons with peripheral arterial diseases
• Persons with acute phlebitis, venous ulcer, congenital vascular anomaly, or Behcet's Syndrome
• Persons with "moderate" or "severe" renal, hepatic, cardiac or haematological disorder, or with a history of such disorder (Grade 3 or 4 in Common Toxicity Criteria (CTC))
• Persons with diabetes mellitus (excluding those curable with dietary therapy), neuropathy, hyper-or hypocalcemia, or malignant tumors
• Persons with drug or alcohol abuse
• Persons with immobility
• Persons with pulmonary embolism
• Persons with hypersensitivity to drugs (particularly to the ingredients contained in the investigational drug)
• Persons with clinical indication of requiring venous treatment such as physical application (use of elastic bandage and compression stockings) and phlebectomy (vein stripping surgery to remove vein affected with varicosis and valve insufficiency)
• Persons who received venous sclerosing therapy within the last 4 weeks before starting this study
• Persons who constantly use theophylline preparations, diuretics, cardiac glycosides
• Persons who had changed to or initiated post-menopausal hormone replacement therapy within the last 2 months before starting this study
• Persons unable to suspend the frequent use and exceeded dosage/administration of laxatives (more than 6 times) during the study period
• Persons planned to undergo a surgery requiring systemic anesthesia during the study period
• Women in pregnancy or nursing, or those who wish for a pregnancy during the study period
• Persons who participated in another study within the last 3 months before starting this study, or who plan to participate in another study during the study period
• Persons who were considered to be ineligible to be a subject for the trial by the investigator or sub-investigators

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1138.6

Identifier Type: -

Identifier Source: org_study_id